Lancet HIV

Article	Citations
HIV infection and COVID-19 death: a population-based cohort analysis of UK primary care data and linked national death registrations within the OpenSAFELY platform	342
The impact of the COVID-19 lockdown on HIV care in 65 South African primary care clinics: an interrupted time series analysis	207
Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in HIV infection: a single-arm substudy of a phase 2/3 clinical trial	188
Overview of SARS-CoV-2 infection in adults living with HIV	141
Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in people living with and without HIV in South Africa: an interim analysis of a randomised, double-blind, placebo-	125
Risk factors for COVID-19-related in-hospital mortality in a high HIV and tuberculosis prevalence setting in South Africa: a cohort study	117
Associations between HIV infection and clinical spectrum of COVID-19: a population level analysis based on US National COVID Cohort Collaborative (N3C) data	111
SARS-CoV-2 seroprevalence, and IgG concentration and pseudovirus neutralising antibody titres after infection, compared by HIV status: a matched case-control observational study	101
Clinical features of, and risk factors for, severe or fatal COVID-19 among people living with HIV admitted to hospital: analysis of data from the WHO Global Clinical Platform of COVID-19	100
Long-acting cabotegravir plus rilpivirine for treatment in adults with HIV-1 infection: 96-week results of the randomised, open-label, phase 3 FLAIR study	99
Life expectancy after 2015 of adults with HIV on long-term antiretroviral therapy in Europe and North America: a collaborative analysis of cohort studies	97
Epidemiology of anal human papillomavirus infection and high-grade squamous intraepithelial lesions in 29 900 men according to HIV status, sexuality, and age: a collaborative pooled analysis of 64 stu	92
Trends in knowledge of HIV status and efficiency of HIV testing services in sub-Saharan Africa, 2000–20: a modelling study using survey and HIV testing programme data	90
Discontinuation, suboptimal adherence, and reinitiation of oral HIV pre-exposure prophylaxis: a global systematic review and meta-analysis	90
Stigma reduction: an essential ingredient to ending AIDS by 2030	82
Safety, uptake, and use of a dapivirine vaginal ring for HIV-1 prevention in African women (HOPE): an open-label, extension study	73
Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 96-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study	72
Adoption of guidelines on and use of oral pre-exposure prophylaxis: a global summary and forecasting study	70
Sociodemographic, clinical, and immunological factors associated with SARS-CoV-2 diagnosis and severe COVID-19 outcomes in people living with HIV: a retrospective cohort study	69
Associations between integrase strand-transfer inhibitors and cardiovascular disease in people living with HIV: a multicentre prospective study from the RESPOND cohort consortium	67
Daily and on-demand HIV pre-exposure prophylaxis with emtricitabine and tenofovir disoproxil (ANRS PREVENIR): a prospective observational cohort study	67
Efficacy and safety of dolutegravir or darunavir in combination with lamivudine plus either zidovudine or tenofovir for second-line treatment of HIV infection (NADIA): week 96 results from a prospecti	66
Long-term protection from HIV infection with oral HIV pre-exposure prophylaxis in gay and bisexual men: findings from the expanded and extended EPIC-NSW prospective implementation study	65
Initiation of long-acting cabotegravir plus rilpivirine as direct-to-injection or with an oral lead-in in adults with HIV-1 infection: week 124 results of the open-label phase 3 FLAIR study	65
Global, regional, and national sex-specific burden and control of the HIV epidemic, 1990–2019, for 204 countries and territories: the Global Burden of Diseases Study 2019	64

Safety and efficacy of the HIV-1 attachment inhibitor prodrug fostemsavir in heavily treatment-experienced individuals: week 96 results of the phase 3 BRIGHTE study	63
Safety, adherence, and HIV-1 seroconversion among women using the dapivirine vaginal ring (DREAM): an open-label, extension study	59
Global and regional epidemiology of HIV-1 recombinants in 1990–2015: a systematic review and global survey	58
The case for an HIV cure and how to get there	57
Epigenetic age acceleration changes 2 years after antiretroviral therapy initiation in adults with HIV: a substudy of the NEAT001/ANRS143 randomised trial	55
The potential effect of COVID-19-related disruptions on HIV incidence and HIV-related mortality among men who have sex with men in the USA: a modelling study	53
HCV micro-elimination in individuals with HIV in the Netherlands 4 years after universal access to direct-acting antivirals: a retrospective cohort study	52
Global estimates of viral suppression in children and adolescents and adults on antiretroviral therapy adjusted for missing viral load measurements: a multiregional, retrospective cohort study in 31 c	51
Long-term safety and efficacy of emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV-1 pre-exposure prophylaxis: week 96 results from a randomised, doubl	51
Effect of SMS reminders on PrEP adherence in young Kenyan women (MPYA study): a randomised controlled trial	50
Age patterns of HIV incidence in eastern and southern Africa: a modelling analysis of observational population-based cohort studies	47
Financial incentives to promote retention in care and viral suppression in adults with HIV initiating antiretroviral therapy in Tanzania: a three-arm randomised controlled trial	46
Viral suppression and HIV-1 drug resistance 1 year after pragmatic transitioning to dolutegravir first-line therapy in Malawi: a prospective cohort study	44
Multi-stakeholder consensus on a target product profile for an HIV cure	43
Contemporary antiretrovirals and body-mass index: a prospective study of the RESPOND cohort consortium	41
Lenacapavir administered every 26 weeks or daily in combination with oral daily antiretroviral therapy for initial treatment of HIV: a randomised, open-label, active-controlled, phase 2 trial	41
Safety and immunogenicity of CoronaVac in people living with HIV: a prospective cohort study	40
Dolutegravir and pregnancy outcomes in women on antiretroviral therapy in Brazil: a retrospective national cohort study	40
Immunogenicity and safety of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine in people living with and without HIV-1 infection: a randomised, controlled, phase 2A/2B trial	40
HIV, chemsex, and the need for harm-reduction interventions to support gay, bisexual, and other men who have sex with men	39
HIV pre-exposure prophylaxis for men who have sex with men in west Africa: a multicountry demonstration study	38
Estimated life expectancy gains with antiretroviral therapy among adults with HIV in Latin America and the Caribbean: a multisite retrospective cohort study	37
Failure to seroconvert after two doses of BNT162b2 SARS-CoV-2 vaccine in a patient with uncontrolled HIV	37
Unified European support framework to sustain the HIV cascade of care for people living with HIV including in displaced populations of war-struck Ukraine	36
Subnational mapping of HIV incidence and mortality among individuals aged 15–49 years in sub-Saharan Africa, 2000–18: a modelling study	36
Isoniazid preventive therapy plus antiretroviral therapy for the prevention of tuberculosis: a systematic review and meta-analysis of individual participant data	36
Integrating HIV and mental health interventions to address a global syndemic among men who have sex with men	34
HIV testing approaches to reach the first UNAIDS 95% target in sub-Saharan Africa	33
How health systems can adapt to a population ageing with HIV and comorbid disease	32
Primary HIV-1 infection in users of pre-exposure prophylaxis	32
Delayed presentation of HIV among older individuals: a growing problem	32
Same-day initiation of oral pre-exposure prophylaxis among gay, bisexual, and other cisgender men who have sex with men and transgender women in Brazil, Mexico, and Peru (ImPrEP): a prospective, singl	30
Intertwined epidemics: progress, gaps, and opportunities to address intimate partner violence and HIV among key populations of women	30
Risk of hepatitis C reinfection following successful therapy among people living with HIV: a global systematic review, meta-analysis, and meta-regression	30
PrEP retention and prescriptions for pregnant women during COVID-19 lockdown in South Africa	30
PrEP awareness and engagement among transgender women in South Africa: a cross-sectional, mixed methods study	30
Long-acting antiretrovirals and HIV treatment adherence	30
HIV-1 drug resistance in people on dolutegravir-based antiretroviral therapy: a collaborative cohort analysis	30
Islatravir in combination with doravirine for treatment-naive adults with HIV-1 infection receiving initial treatment with islatravir, doravirine, and lamivudine: a phase 2b, randomised, double-blind,	29
Implementation and outcomes of dolutegravir-based first-line antiretroviral therapy for people with HIV in South Africa: a retrospective cohort study	29
Same-day prescribing of daily oral pre-exposure prophylaxis for HIV prevention	28
Efficiency of 6-month PrEP dispensing with HIV self-testing in Kenya: an open-label, randomised, non-inferiority, implementation trial	27
Associations between punitive policies and legal barriers to consensual same-sex sexual acts and HIV among gay men and other men who have sex with men in sub-Saharan Africa: a multicountry, respondent	26
The risk of mental illness in people living with HIV in the UK: a propensity score-matched cohort study	26
72 weeks post-partum follow-up of dolutegravir versus efavirenz initiated in late pregnancy (DolPHIN-2): an open-label, randomised controlled study	26
Adolescent participation in HIV research: consortium experience in low and middle-income countries and scoping review	25
Perceived HIV stigma and HIV testing among men and women in rural Uganda: a population-based study	25
Predicted effects of the introduction of long-acting injectable cabotegravir pre-exposure prophylaxis in sub-Saharan Africa: a modelling study	24
Where are the pregnant and breastfeeding women in new pre-exposure prophylaxis trials? The imperative to overcome the evidence gap	24
Effects of implementing universal and rapid HIV treatment on initiation of antiretroviral therapy and retention in care in Zambia: a natural experiment using regression discontinuity	24

Relative cost-effectiveness of long-acting injectable cabotegravir versus oral pre-exposure prophylaxis in South Africa based on the HPTN 083 and HPTN 084 trials: a modelled economic evaluation and th	23
A 4-days-on and 3-days-off maintenance treatment strategy for adults with HIV-1 (ANRS 170 QUATUOR): a randomised, open-label, multicentre, parallel, non-inferiority trial	23
COVID-19 death in people with HIV: interpret cautiously	22
Trends and risk of lung cancer among people living with HIV in the USA: a population-based registry linkage study	22
HIV burden and correlates of infection among transfeminine people and cisgender men who have sex with men in Nairobi, Kenya: an observational study	22
Prioritising pleasure and correcting misinformation in the era of U=U	22
Status of the HIV epidemic in key populations in the Middle East and north Africa: knowns and unknowns	22
Home-based oral self-testing for absent and declining individuals during a door-to-door HIV testing campaign in rural Lesotho (HOSENG): a cluster-randomised trial	21
Variations in the characteristics and outcomes of children living with HIV following universal ART in sub-Saharan Africa (2006–17): a retrospective cohort study	21
Weekly 17 alpha-hydroxyprogesterone caproate to prevent preterm birth among women living with HIV: a randomised, double-blind, placebo-controlled trial	21
Tuberculosis screening among HIV-positive inpatients: a systematic review and individual participant data meta-analysis	21
Universal test-and-treat in Zambian and South African correctional facilities: a multisite prospective cohort study	20
Standard-dose versus double-dose dolutegravir in HIV-associated tuberculosis in South Africa (RADIANT-TB): a phase 2, non-comparative, randomised controlled trial	20
Burden of living with HIV among men who have sex with men: a mixed-methods study	20
HIV incidence and mortality in transgender women in the eastern and southern USA: a multisite cohort study	20
HIV care cascade and associated factors among men who have sex with men, transgender women, and genderqueer individuals in Zimbabwe: findings from a biobehavioural survey using respondent-driven sampl	20
Dolutegravir dosing for children with HIV weighing less than 20 kg: pharmacokinetic and safety substudies nested in the open-label, multicentre, randomised, non-inferiority ODYSSEY trial	20
Cost-effectiveness of easy-access, risk-informed oral pre-exposure prophylaxis in HIV epidemics in sub-Saharan Africa: a modelling study	20
Efficacy, safety, and tolerability of switching to long-acting cabotegravir plus rilpivirine versus continuing fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide in virologically suppres	19
Temporal change in population-level prevalence of detectable HIV viraemia and its association with HIV incidence in key populations in India: a serial cross-sectional study	19
Estimates of the prevalence of undiagnosed HIV among children living with HIV in Eswatini, Lesotho, Malawi, Namibia, Tanzania, Zambia, and Zimbabwe from 2015 to 2017: an analysis of data from the cros	19
Health system adaptations and considerations to facilitate optimal oral pre-exposure prophylaxis scale-up in sub-Saharan Africa	18
Efficacy and safety of the novel capsid inhibitor lenacapavir to treat multidrug-resistant HIV: week 52 results of a phase 2/3 trial	18
Trends in HIV testing, the treatment cascade, and HIV incidence among men who have sex with men in Africa: a systematic review and meta-analysis	18
The future of HIV pre-exposure prophylaxis adherence: reducing barriers and increasing opportunities	18
Pharmacokinetics, safety, tolerability, and antiviral activity of dolutegravir dispersible tablets in infants and children with HIV-1 (IMPAACT P1093): results of an open-label, phase 1–2 trial	18
Efficacy and safety of switching to dolutegravir plus lamivudine versus continuing triple antiretroviral therapy in virologically suppressed adults with HIV at 48 weeks (DOLAM): a randomised non-infer	17
Living with COVID-19 and preparing for future pandemics: revisiting lessons from the HIV pandemic	17
Two-drug regimens for HIV treatment	17
Costs and impact on HIV transmission of a switch from a criminalisation to a public health approach to injecting drug use in eastern Europe and central Asia: a modelling analysis	17
Free HIV self-test for identification and linkage to care of previously undetected HIV infection in men who have sex with men in England and Wales (SELPHI): an open-label, internet-based, randomised c	17
HIV clinic-based buprenorphine plus naloxone versus referral for methadone maintenance therapy for treatment of opioid use disorder in HIV clinics in Vietnam (BRAVO): an open-label, randomised, non-in	17
Adherence, safety, and choice of the monthly dapivirine vaginal ring or oral emtricitabine plus tenofovir disoproxil fumarate for HIV pre-exposure prophylaxis among African adolescent girls and young	17
Incorporating oral PrEP into standard prevention services for South African women: a nested interrupted time-series study	16
Scaling up access to HIV pre-exposure prophylaxis (PrEP): should nurses do the job?	16
Adult HIV-1 incidence across 15 high-burden countries in sub-Saharan Africa from 2015 to 2019: a pooled analysis of nationally representative data	16
HIV treatment-as-prevention and its effect on incidence of HIV among cisgender gay, bisexual, and other men who have sex with men in Australia: a 10-year longitudinal cohort study	16
Disparities in breast cancer survival between women with and without HIV across sub-Saharan Africa (ABC-DO): a prospective, cohort study	16
Outcomes of people living with HIV after hospital discharge: a systematic review and meta-analysis	16
The effects of intimate partner violence on women's risk of HIV acquisition and engagement in the HIV treatment and care cascade: a pooled analysis of nationally representative surveys in sub-Saharan	15
Application of artificial intelligence and machine learning for HIV prevention interventions	15
Hypogonadism and bone health in men with HIV	15
Efficacy and safety of three antiretroviral therapy regimens started in pregnancy up to 50 weeks post partum: a multicentre, open-label, randomised, controlled, phase 3 trial	15
Adolescent retention in HIV care within differentiated service-delivery models in sub-Saharan Africa	15
Improving health equity and ending the HIV epidemic in the USA: a distributional cost-effectiveness analysis in six cities	15
Alignment of PrEP adherence with periods of HIV risk among adolescent girls and young women in South Africa and Zimbabwe: a secondary analysis of the HPTN 082 randomised controlled trial	15
Trends in suicide mortality among people with HIV after diagnosis during 2012–18: a retrospective, national cohort study in China	15
HIV incidence estimation among female sex workers in South Africa: a multiple methods analysis of cross-sectional survey data	15
Global HIV control: is the glass half empty or half full?	14
Kidney function in tenofovir disoproxil fumarate-based oral pre-exposure prophylaxis users: a systematic review and meta-analysis of published literature and a multi-country meta-analysis of individua	14
Dolutegravir twice-daily dosing in children with HIV-associated tuberculosis: a pharmacokinetic and safety study within the open-label, multicentre, randomised, non-inferiority ODYSSEY trial	14
Cost-effectiveness of point-of-care testing with task-shifting for HIV care in South Africa: a modelling study	14
A tale of four studies: HIV vaccine immunogenicity and efficacy in clinical trials	14
A Bayesian averted infection framework for PrEP trials with low numbers of HIV infections: application to the results of the DISCOVER trial	14
The effect of providing women sustained access to HIV self-tests on male partner testing, couples testing, and HIV incidence in Kenya: a cluster-randomised trial	14
Epidemiology of severe COVID-19 from South Africa	13
Once-daily dolutegravir-based antiretroviral therapy in infants and children living with HIV from age 4 weeks: results from the below 14 kg cohort in the randomised ODYSSEY trial	13
Dolutegravir and pregnancy outcomes including neural tube defects in the USA during 2008–20: a national cohort study	13
Associations of modern initial antiretroviral drug regimens with all-cause mortality in adults with HIV in Europe and North America: a cohort study	13
Safety and pharmacokinetics of escalating doses of neutralising monoclonal antibody CAP256V2LS administered with and without VRC07-523LS in HIV-negative women in South Africa (CAPRISA 012B): a phase 1	13
Equity in access to long-acting injectables in the USA	13
Pharmacokinetics and safety of early nevirapine-based antiretroviral therapy for neonates at high risk for perinatal HIV infection: a phase 1/2 proof of concept study	13
Long-term virological outcomes in women who started option B+ care during pregnancy for prevention of mother-to-child transmission of HIV in Dar es Salaam, Tanzania: a cohort study	12
Protease inhibitor-based antiretroviral therapy in pregnancy: effects on hormones, placenta, and decidua	12
Messaging matters: achieving equity in the HIV response through public health communication	12
Efficacy and safety of long-acting cabotegravir compared with daily oral tenofovir disoproxil fumarate plus emtricitabine to prevent HIV infection in cisgender men and transgender women who have sex w	12
Advancing the prevention and treatment of HIV in children: priorities for research and development	12
Effects of clinical, comorbid, and social determinants of health on brain ageing in people with and without HIV: a retrospective case-control study	11
Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, emtricitabine, and tenofovir disoproxil fumarate for initial treatment of HIV-1 and hepatitis B coinfection (ALLIANCE): a dou	11
HIV among migrants in precarious circumstances in the EU and European Economic Area	11
Cancer risk in adolescents and young adults living with HIV in South Africa: a nationwide cohort study	11
Tracking elimination of HIV transmission in men who have sex with men in England: a modelling study	11
Long-term evolution of comorbidities and their disease burden in individuals with and without HIV as they age: analysis of the prospective AGEhIV cohort study	11
More evidence for worse COVID-19 outcomes in people with HIV	11
Effect of a conditional cash transfer programme on AIDS incidence, hospitalisations, and mortality in Brazil: a longitudinal ecological study	10
Rates of viral suppression in a cohort of people with stable HIV from two community models of ART delivery versus facility-based HIV care in Lusaka, Zambia: a cluster-randomised, non-inferiority trial	10
Pregnancy and neonatal safety outcomes of timing of initiation of daily oral tenofovir disoproxil fumarate and emtricitabine pre-exposure prophylaxis for HIV prevention (CAP016): an open-label, random	10
Expansion of PrEP and PEP services in China	10
Safety, immunogenicity, and transplacental antibody transport of conjugated and polysaccharide pneumococcal vaccines administered to pregnant women with HIV: a multicentre randomised controlled trial	10
Longitudinal trends in causes of death among adults with HIV on antiretroviral therapy in Europe and North America from 1996 to 2020: a collaboration of cohort studies	10

HIV criminalisation laws and ending the US HIV epidemic	10
Opt-out HIV testing in the UK	9
HIV incidence trends in Africa: young women at highest risk	9
Monkeypox vaccination—an opportunity for HIV prevention	9
Differences in healthy longevity by HIV status and viral load among older South African adults: an observational cohort modelling study	9
HIV incidence and impact of interventions among female sex workers and their clients in the Middle East and north Africa: a modelling study	9
Trends in HIV prevalence, incidence, and progress towards the UNAIDS 95-95-95 targets in Malawi among individuals aged 15–64 years: population-based HIV impact assessments, 2015−16 and 2020−21	9
No woman left behind: achieving cervical cancer elimination among women living with HIV	9
Russia's invasion of Ukraine threatens HIV response	9
Menopausal hormone therapy for women living with HIV	9
Programme science: a route to effective coverage and population-level impact for HIV and sexually transmitted infection prevention	8
The HIV care continuum for sexually active transgender women in three metropolitan municipalities in South Africa: findings from a biobehavioural survey 2018–19	8
Time to tackle late diagnosis	8
Harm reduction for smokers living with HIV	8
Safety, tolerability, pharmacokinetics, and immunological activity of dual-combinations and triple-combinations of anti-HIV monoclonal antibodies PGT121, PGDM1400, 10-1074, and VRC07-523LS administere	8
Prophylactic HIV-1 vaccine trials: past, present, and future	8
The potential impact of country-level migration networks on HIV epidemics in sub-Saharan Africa: the case of Botswana	8
Community-based HIV testing services in an urban setting in western Kenya: a programme implementation study	8
Effect of the introduction of screening for cancer precursor lesions on anal cancer incidence over time in people living with HIV: a nationwide cohort study	8
Immunological and virological findings in a patient with exceptional post-treatment control: a case report	7
Is the USA on track to end the HIV epidemic?	7
Potential health benefits of integrated screening strategies for alcohol, tobacco, other substance use, depression, anxiety, and chronic pain among people living with HIV in the USA: a mathematical mo	7
Fee for home delivery and monitoring of antiretroviral therapy for HIV infection compared with standard clinic-based services in South Africa: a randomised controlled trial	7
Transition to independent care for youth living with HIV: a cluster randomised clinical trial	7
Comparison of index-linked HIV testing for children and adolescents in health facility and community settings in Zimbabwe: findings from the interventional B-GAP study	7
Prioritise people with HIV for COVID-19 vaccination	7
A community mobilisation intervention to improve engagement in HIV testing, linkage to care, and retention in care in South Africa: a cluster-randomised controlled trial	7
Dolutegravir drug-resistance monitoring in Africa	7
Use of integrase inhibitors in HIV-associated tuberculosis in high-burden settings: implementation challenges and research gaps	7
HIV pre-exposure prophylaxis and its implementation in the PrEP Impact Trial in England: a pragmatic health technology assessment	7
COVID-19 threatens HIV care continuity in Brazil	7
Non-communicable diseases in older people living with HIV in four African countries: a cohort study	7
The need for a health equity framework in next-generation pre-exposure prophylaxis implementation	7
Risks and benefits of oral HIV pre-exposure prophylaxis for people with chronic hepatitis B	7
Abacavir dosing in neonates from birth to 3 months of life: a population pharmacokinetic modelling and simulation study	7
Brazil sustains HIV response during the COVID-19 pandemic	6
Pharmacokinetics, safety, and tolerability of dispersible and immediate-release abacavir, dolutegravir, and lamivudine tablets in children with HIV (IMPAACT 2019): week 24 results of an open-label, mu	6
The case for prescribing PrEP in community mental health settings	6
Changes in incidence of hepatitis C virus reinfection and access to direct-acting antiviral therapies in people with HIV from six countries, 2010–19: an analysis of data from a consortium of prospecti	6
Equitable access to long-acting PrEP on the way?	6
SARS-CoV-2 vaccination in people with HIV	6
Barriers and facilitators to HIV pre-exposure prophylaxis for cisgender and transgender women in the UK	6
A focus on disability is necessary to achieve HIV epidemic control	6
Factors associated with HIV infection among children in Larkana District, Pakistan: a matched case-control study	6
Post-exposure prophylaxis to prevent HIV: new drugs, new approaches, and more questions	6
Safety of teropavimab and zinlirvimab with lenacapavir once every 6 months for HIV treatment: a phase 1b, randomised, proof-of-concept study	6
So many harms, so little benefit: a global review of the history and harms of HIV criminalisation	6
Improvements in transition times through the HIV cascade of care among gay and bisexual men with a new HIV diagnosis in New South Wales and Victoria, Australia (2012–19): a longitudinal cohort study	6
Maintaining ART services during COVID-19 border closures: lessons learned in Namibia	6
Cost-effectiveness of point-of-care versus centralised, laboratory-based nucleic acid testing for diagnosis of HIV in infants: a systematic review of modelling studies	6
A mid-level health manager intervention to promote uptake of isoniazid preventive therapy among people with HIV in Uganda: a cluster randomised trial	6
HIV care continuum interventions for Black men who have sex with men in the USA	6
What babies need: accelerating access to current and novel antiretroviral drugs in neonates through pharmacokinetic studies	6
Developing tuberculosis vaccines for people with HIV: consensus statements from an international expert panel	6
HIV epidemiology in the WHO Eastern Mediterranean region: a multicountry programme review	6
We should not stop considering HIV drug resistance testing at failure of first-line antiretroviral therapy	6
UNAIDS strategy aligns HIV priorities with development goals	6
HIV infection and engagement in the care continuum among migrants and refugees from Venezuela in Colombia: a cross-sectional, biobehavioural survey	6
A multilevel health system intervention for virological suppression in adolescents and young adults living with HIV in rural Kenya and Uganda (SEARCH-Youth): a cluster randomised trial	6
Benefits of early ART initiation on mortality among people with HIV	6
A collision of pandemics: HIV and COVID-19	5
Ukraine adapts its HIV response	5
Drug resistance and use of long-acting ART	5
Need for transgender-specific data from Africa and elsewhere	5
What future for HIV vaccines?	5
Integrase strand-transfer inhibitor use and cardiovascular events in adults with HIV: an emulation of target trials in the HIV-CAUSAL Collaboration and the Antiretroviral Therapy Cohort Collaboration	5
Effects of long-term antiretroviral therapy in reproductive-age women in sub-Saharan Africa (the PEPFAR PROMOTE study): a multi-country observational cohort study	5
Making PrEP easy	5
HIV combination prevention and declining orphanhood among adolescents, Rakai, Uganda, 2001–18: an observational community cohort study	5
Time to end discriminatory laws against people with HIV	5
Reduction in mortality from HIV-related CNS infections in routine care in Africa (DREAMM): a before-and-after, implementation study	5
Defining principles for a choice-based approach to HIV prevention	5
Acceptability and tolerability of long-acting injectable cabotegravir or rilpivirine in the first cohort of virologically suppressed adolescents living with HIV (IMPAACT 2017/MOCHA): a secondary analy	5
The last Black man with HIV in San Francisco: the potential role of gentrification on HIV getting to zero achievements	5
Funding the future of the HIV response	5
Advanced HIV disease and health-related suffering—exploring the unmet need of palliative care	5
International Women's Day—how can I help?	5
Viral suppression and self-reported ART adherence after 3 years of universal testing and treatment in the HPTN 071 (PopART) community-randomised trial in Zambia and South Africa: a cross-sectional ana	5
Checklist for studies of HIV drug resistance prevalence or incidence: rationale and recommended use	5
Efficacy, safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir for HIV pre-exposure prophylaxis in transgender women: a secondary analysis of the HPTN 083 trial	4
Progress towards the UNAIDS 95-95-95 targets in the Fifth Botswana AIDS Impact Survey (BAIS V 2021): a nationally representative survey	4
Gender-affirmative systems needed for PrEP implementation	4
PrEP dispensing with HIV self-testing	4
Observed CD4 counts at entry into HIV care and at antiretroviral therapy prescription by age in the USA, 2004–18: a cohort study	4
Effect of screening for Neisseria gonorrhoeae and Chlamydia trachomatis on incidence of these infections in men who have sex with men and transgender women taking HIV pre-exposure prophylaxis (the Gon	4
Associations between change in BMI and the risk of hypertension and dyslipidaemia in people receiving integrase strand-transfer inhibitors, tenofovir alafenamide, or both compared with other contempor	4
The path to elimination of vertical transmission of HIV	4
Diagnosis of liver fibrosis in ageing patients with HIV at risk for non-alcoholic fatty liver disease in Italy and Canada: assessment of a two-tier pathway	4
The effect of the Xpert HIV-1 Qual test on early infant diagnosis of HIV in Myanmar and Papua New Guinea: a pragmatic, cluster-randomised, stepped-wedge, open-label trial	4
SARS-CoV-2 immunity and HIV infection: total recall?	4
Innovations, adaptations, and accelerations in the delivery of HIV services during COVID-19	4
Addressing inequalities still key to ending HIV/AIDS	4
Implementation of PrEP in Latin America	4
Lessons from dolutegravir and neural tube defects	4
Fate of people with HIV in jeopardy in Ukraine	4